The estimated Net Worth of Simon N. Pimstone is at least $13.7 Million dollars as of 30 May 2023. Simon Pimstone owns over 134,153 units of Xenon Pharmaceuticals Inc stock worth over $1,971,150 and over the last 10 years he sold XENE stock worth over $9,146,898. In addition, he makes $2,612,720 as Chief Executive Officer and Director at Xenon Pharmaceuticals Inc.
Simon has made over 14 trades of the Xenon Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 134,153 units of XENE stock worth $2,052,541 on 30 May 2023.
The largest trade he's ever made was selling 177,135 units of Xenon Pharmaceuticals Inc stock on 12 August 2022 worth over $6,775,414. On average, Simon trades about 21,780 units every 102 days since 2014. As of 30 May 2023 he still owns at least 51,000 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Simon Pimstone stock trades at the bottom of the page.
Dr. Simon Neil Pimstone Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Pimstone has been a Consultant Physician at the University of British Columbia Hospital, Cardiology Clinic, and since 2014, he has held the position of Clinical Associate Professor at the University of British Columbia, Division of General Internal Medicine. Currently, Dr. Pimstone is an Investigator at the Centre for Heart Lung Innovation (HLI) research centre. Dr. Pimstone currently serves as chair of the board of Eupraxia Pharmaceuticals Inc., Accuro Technologies, and TopiRx Pharmaceuticals, three private specialty pharmaceutical companies, where he has served as a director since 2012, 2012 and 2019, respectively. Dr. Pimstone holds an MBChB from the University of Cape Town, a FRCPC from the University of British Columbia, and a Ph.D. from the University of Amsterdam in cardiovascular genetics. Dr. Pimstone is a former director of Indel Therapeutics Inc., Cyon Therapeutics Inc. and Enject, Inc. Previously, Dr. Pimstone was director and chair of the board of directors of LifeSciences British Columbia, a non-profit industry association that supports the life science community, and a former director of the Providence Healthcare Research Trust, BC Advantage Life Sciences Fund, Centre for Molecular Medicine and Therapeutics, BIOTECanada, and BC Health Research Strategy Advisory Board of the Michael Smith Foundation for Health Research. Our Board believes that Dr. Pimstone is qualified to serve as a director because of his executive leadership experience, many years of service on our Board and as our Chief Executive Officer and his knowledge and perspective of the Corporation.
As the Chief Executive Officer and Director of Xenon Pharmaceuticals Inc, the total compensation of Simon Pimstone at Xenon Pharmaceuticals Inc is $2,612,720. There are no executives at Xenon Pharmaceuticals Inc getting paid more.
Simon Pimstone is 52, he's been the Chief Executive Officer and Director of Xenon Pharmaceuticals Inc since 2018. There are 16 older and 6 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.
Simon's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, Z4, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog..., and Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: